Clinical and laboratory aspects of Mycobacterium haemophilum infections

Reviews and Research in Medical Microbiology

Volumn 9, Issue 1, 1998, Pages 49-54

  LaBombardi, V J ^a,b   Nord, J A ^a,b  

^a ST VINCENT S HOSPITAL   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Immunosuppression; Lymphadenitis; Mycobacterium haemophilum; Non tuberculous mycobacteria; Opportunistic infections; Skin lesions

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; DOXYCYCLINE; ETHAMBUTOL; ETHIONAMIDE; FERRIC ION; HEMIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

BACTERIAL GROWTH; DISEASE TRANSMISSION; HUMAN; IMMUNE DEFICIENCY; LABORATORY TEST; LYMPHADENOPATHY; MYCOBACTERIOSIS; MYCOBACTERIUM HAEMOPHILUM; PRIORITY JOURNAL; REVIEW; SKIN DEFECT;

EID: 0031973447     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-199801000-00006     Document Type: Review

References (13)

1. Sompolinsky D, Lagziel A, Naveh D, Yankilevitz T. Mycobacterium haemophilum sp. nov., a new pathogen of humans. Int J Syst Bact 1978; 28: 67-75.
2. Feldman RA, Herschfield E. Mycobacterial skin infection by an unidentified species: a report of 29 patients. Ann Int Med 1974; 80: 445-452.
3. Lomvardias S, Madge GE. Chaetoconidium and atypical acid fast bacilli in skin ulcers. Arch Derm 1972; 106: 875-876.
4. Dawson DJ, Jennis F. Mycobacteria with a growth requirement for ferric ammonium citrate, identified as Mycobacterium haemophilum. J Clin Microbiol 1980; 11: 190-192.
5. Dawson DJ, Blacklock ZM, Kane DW. Mycobacterium haemophilum causing lymphadenitis in an otherwise healthy child. Med J Aust 1981; 2: 289-290.
6. Goslee S, Wolinsky E. Water as a source of potentially pathogenic mycobacteria. Am Rev Respir Dis 1976; 113: 287-292.
7. LaBombardi V. Mycobacterium haemophilum infections in immunocompromised patients. Lab Medica Intl 1992; 9: 31-33.
8. Atkinson BA, Bocanegra R, Graybill JR. Treatment of Mycobacterium haemophilum infections in a murine model with clarithromycin, rifabutin and ciprofloxacin. Antimicrob Agents Chemother 1995; 39: 2316-2319.
9. LaBombardi VJ, Lukowski C. Anti-tubercular susceptibility testing using the Difco ESP Myco system. Abst Gen Meet American Society of Microbiology, Miami, FL 4-8 May, 1997; U75 p. 556.
10. McGovern J, Bix BC, Webster GW. Mycobacterium haemophilum skin disease successfully treated with excision. J Am Acad Dermatol 1994; 30: 269-270.
11. Darling TN, Sidhu-Malik N, Correy GR et al. Treatment of Mycobacterium haemophilum infection with an antibiotic regimen including clarithromycin. Br J Dermatol 1994; 131: 376-379.
12. Centers for Disease Control: Mycobacterium haemophilum infections. New York City Metropolitan area, 1990-1991 MMWR 1991; 40: 636-637, 643.
13. Dever LL, Martin JW, Seaworth B et al. Varied presentations and responses to treatment of infections caused by Mycobacterium haemophilum in patients with AIDS. Clin Infect Dis 1992; 14: 1195-1200.